TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Geriatrics Society has published a case-based framework for clinicians prescribing obesity medications, including GLP-1 therapies, to older adults. It recommends weighing treatment decisions against functional status, nutrition, cognition and risks such as muscle loss, and pairing medication with supports including resistance exercise and adequate protein.
The American Geriatrics Society (AGS) has released a case-based framework to help clinicians prescribe obesity medications safely for older adults, including medicines that act through incretin pathways such as GLP-1 therapies. Published in the Journal of the American Geriatrics Society, the paper advises clinicians to assess patients’ function, nutrition and cognition before treatment and to consider risks including frailty and loss of lean muscle.
Developed by the AGS Healthy Aging Special Interest Group, the framework applies the society’s Geriatrics 5Ms—Mind, Mobility, Medications, Multicomplexity and Matters Most—to obesity medication decisions. It is organized around clinical cases and is intended as a practical way to consider how treatment fits an older person’s health, abilities and priorities.
The authors call for a pretreatment assessment of functional status, nutritional adequacy and cognitive impairment. They also emphasize potential concerns for older adults, including sarcopenia, frailty, lean muscle loss, malnutrition and dehydration. The report says older adults have been underrepresented in clinical trials, leaving clinicians with less evidence specific to this population.
The framework recommends pairing medication with supportive measures, including resistance training and adequate dietary protein. Depending on an individual’s needs, care may involve a registered dietitian, physical therapist, fitness trainer or behavioral health professional. The article describes these as considerations for clinical care, not a one-size-fits-all treatment plan.
Balancing Weight Treatment With Healthy Aging
The framework addresses a practical challenge: medication decisions for older adults may need to account for more than weight or blood sugar outcomes. Changes in strength, mobility, appetite, hydration and ability to manage treatment can affect whether a plan is appropriate and how it should be monitored. The AGS approach puts those factors alongside the person’s own priorities.
Its emphasis on muscle preservation and nutrition matters because weight loss can involve loss of lean tissue as well as fat. The source does not quantify that risk for particular medicines or patients, but it identifies it as a consideration clinicians should weigh. The framework therefore pairs prescribing with attention to function and supportive care rather than treating medication as a stand-alone intervention.
For patients and caregivers, the report offers a prompt to discuss goals, nutritional needs, physical activity, other medicines and practical support with a clinician. It does not establish that every older adult should receive obesity medication, nor does it report new trial results or demonstrate the effectiveness of a specific prescribing strategy.
Products Worth Considering
BowFlex Results Series SelectTech Adjustable Dumbbells, Pair
Fitbit Versa Smart Watch – Black Aluminum, One Size (S & L Bands Included)
Bowflex SelectTech 840 Adjustable Kettlebell
As an affiliate, we earn on qualifying purchases.
Applying the Geriatrics 5Ms to Medication
The paper, by Elias M. Wisdom and co-authors, is titled “Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.” It appeared in the Journal of the American Geriatrics Society in 2026, with DOI 10.1111/jgs.70769.
The 5Ms are a geriatrics framework that organizes care around Mind, Mobility, Medications, Multicomplexity and Matters Most. In this paper, the approach is applied to incretin therapy and other obesity medication decisions. The report notes that obesity medicines may offer benefits for weight management, glycemic control and other health conditions, while also stressing that older adults are underrepresented in clinical studies.
The source describes the publication as guidance for clinicians, not a clinical trial, prescribing mandate or formal drug approval. Its case-based format is intended to help practitioners account for differences among older patients when considering treatment.
“The framework applies the Geriatrics 5Ms Framework—Mind, Mobility, Medications, Multicomplexity, and Matters Most—to incretin therapy in older adults.”
— The AGS framework authors
Evidence Gaps in Older Patients
The source does not provide trial data showing how well the framework works in practice, nor does it compare particular medications or specify which patients should receive them. It also does not give drug-specific estimates for muscle loss, dehydration or other risks. The report’s concern that older adults are underrepresented in trials means the evidence base for this age group remains limited, but the source does not quantify the size of that gap.
It is not clear from the report how the authors expect clinicians to translate each case into decisions for patients with different levels of frailty, cognitive impairment or nutritional risk. The framework does not replace an individualized assessment or provide a universal dosing plan. Whether its recommendations will be adopted widely, and whether they change patient outcomes, remains to be seen.
Clinical Use and Further Evidence
The framework is now available to clinicians through its publication in the Journal of the American Geriatrics Society. Practitioners can use its case-based 5Ms approach to guide discussions about treatment goals, functional capacity, diet, exercise and the supports a patient may need. Patients considering these medicines should discuss their own health conditions, current medications and priorities with a qualified clinician.
The report does not announce a follow-up study, implementation schedule or planned revision. Further research involving older adults would help clarify how medication benefits and risks vary with age, frailty and nutritional status, and whether team-based supports improve outcomes. For now, the paper presents a clinical framework, while the evidence and its effects in routine care remain developing.
Key Questions
What did the American Geriatrics Society publish?
The AGS published a case-based framework for clinicians considering obesity medications for older adults. It uses the Geriatrics 5Ms to structure patient-centered prescribing decisions.
Which factors does the framework ask clinicians to assess?
It recommends assessing functional status, nutritional adequacy and cognitive impairment before treatment. It also flags frailty, sarcopenia, lean muscle loss, malnutrition and dehydration as considerations.
Does the framework recommend medication for every older adult with obesity?
No. The source describes a decision-making framework, not a blanket recommendation or prescribing mandate. Treatment decisions should reflect an individual’s health, function, needs and priorities.
What support may be paired with obesity medication?
The authors recommend considering resistance training and adequate dietary protein. Some patients may benefit from support involving professionals such as a dietitian or physical therapist, based on their circumstances.
What remains uncertain?
The source does not report trials testing the framework or establish how it affects outcomes. It also notes that older adults are underrepresented in clinical trials, leaving important questions about medication use in this population.
Source: medicalxpress.com
